Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > SPI-2012

SPI-2012Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

SPI-2012, Spectrum's third biological drug, is a long-acting Granulocyte Colony-Stimulating Factor (GCSF) that utilizes Hanmi Pharmaceuticals proprietary platform technology, LAPSCOVERYTM.

Granulocyte colony-stimulating factor stimulates the production of white blood cells by the bone marrow. A recombinant form of GCSF is used in appropriate cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens to be given at full-dose and on schedule. Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections, hospitalizations, and interruption of additional chemotherapy treatments.

Target Indications

  • Chemotherapy induced neutropenia

Route of Administration

  • Subcutaneous injection

Mode of Action

Animal data is suggestive of:

  • Neuroprotective and nerve sprouting effects mediated through several nerve growth factors
  • Benefits in chemotherapy-induced neuropathy in experimental models

Status

  • In a U.S. based Phase 1 study in healthy volunteers, SPI-2012 demonstrated activity similar to Neulasta (pegfilgrastim) at one-third the dose
  • Phase 2 Study of SPI-2012 for the Treatment of Chemotherapy-Induced Neutropenia initiated in 2013 with Hanmi Pharmaceuticals

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Market OpportunitiesSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

  • SPI-2012 could have potential advantages for more rapid and profound granulocyte recovery in patients with chemotherapy induced neutropenia, a multibillion dollar worldwide market
  • If SPI-2012 is ultimately commercialized, Spectrum shall own worldwide rights except for Korea, China, and Japan.
SPI-2012